Managed Ventricular Pacing in Pediatric Patients and Patients With Congenital Heart Disease

Jonathan R. Kaltman, Pamela S. Ro, Frank Zimmerman, Jeffrey P. Moak, Michael Epstein, Ilana J. Zeltser, Maully J. Shah, Karen Buck, Victoria L. Vetter, Ronn E. Tanel

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Ventricular dyssynchrony induced by ventricular pacing (VP) may predispose patients to congestive heart failure. The detrimental effects of VP are directly related to the cumulative percentage of VP (Cum%VP). Managed VP (MVP) is a novel pacing algorithm developed to minimize unnecessary VP by uncoupling atrial pacing from VP. This retrospective analysis assessed the feasibility of using MVP in pediatric patients and patients with congenital heart disease (CHD). A multicenter review evaluated all pediatric patients <22 years old and older patients with CHD that had an implanted device using a MVP algorithm. Primary outcome variables were Cum%VP and adverse events. A subgroup analysis evaluated patients that had a DDD(R) pacemaker before a MVP device and compared Cum%VP before and after initiation of MVP. From 6 centers 62 patients (mean age 21.5 ± 9.6 years) were included; 64% had CHD. With a MVP device, mean Cum%VP was 4.3 ± 14.6% (range 0 to 83.7): Eleven patients were eligible for subgroup analysis. Compared with DDD(R), Cum%VP significantly decreased with MVP (67.1 ± 29.4% vs 9.2 ± 24.8%, p = 0.002). One MVP-related adverse event occurred; a patient with intermittent atrioventricular block had symptoms with frequent nonconducted atrial depolarizations and was reprogrammed to DDD. In conclusion, MVP can be used safely and can significantly reduce unnecessary VP in pediatric patients and patients with CHD.

Original languageEnglish (US)
Pages (from-to)875-878
Number of pages4
JournalAmerican Journal of Cardiology
Volume102
Issue number7
DOIs
StatePublished - Oct 1 2008

Fingerprint

Heart Diseases
Pediatrics
Dichlorodiphenyldichloroethane
Equipment and Supplies
Atrioventricular Block
Heart Failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Managed Ventricular Pacing in Pediatric Patients and Patients With Congenital Heart Disease. / Kaltman, Jonathan R.; Ro, Pamela S.; Zimmerman, Frank; Moak, Jeffrey P.; Epstein, Michael; Zeltser, Ilana J.; Shah, Maully J.; Buck, Karen; Vetter, Victoria L.; Tanel, Ronn E.

In: American Journal of Cardiology, Vol. 102, No. 7, 01.10.2008, p. 875-878.

Research output: Contribution to journalArticle

Kaltman, JR, Ro, PS, Zimmerman, F, Moak, JP, Epstein, M, Zeltser, IJ, Shah, MJ, Buck, K, Vetter, VL & Tanel, RE 2008, 'Managed Ventricular Pacing in Pediatric Patients and Patients With Congenital Heart Disease', American Journal of Cardiology, vol. 102, no. 7, pp. 875-878. https://doi.org/10.1016/j.amjcard.2008.05.028
Kaltman, Jonathan R. ; Ro, Pamela S. ; Zimmerman, Frank ; Moak, Jeffrey P. ; Epstein, Michael ; Zeltser, Ilana J. ; Shah, Maully J. ; Buck, Karen ; Vetter, Victoria L. ; Tanel, Ronn E. / Managed Ventricular Pacing in Pediatric Patients and Patients With Congenital Heart Disease. In: American Journal of Cardiology. 2008 ; Vol. 102, No. 7. pp. 875-878.
@article{ecbca5d32c864c0998496ad9f392a3e4,
title = "Managed Ventricular Pacing in Pediatric Patients and Patients With Congenital Heart Disease",
abstract = "Ventricular dyssynchrony induced by ventricular pacing (VP) may predispose patients to congestive heart failure. The detrimental effects of VP are directly related to the cumulative percentage of VP (Cum{\%}VP). Managed VP (MVP) is a novel pacing algorithm developed to minimize unnecessary VP by uncoupling atrial pacing from VP. This retrospective analysis assessed the feasibility of using MVP in pediatric patients and patients with congenital heart disease (CHD). A multicenter review evaluated all pediatric patients <22 years old and older patients with CHD that had an implanted device using a MVP algorithm. Primary outcome variables were Cum{\%}VP and adverse events. A subgroup analysis evaluated patients that had a DDD(R) pacemaker before a MVP device and compared Cum{\%}VP before and after initiation of MVP. From 6 centers 62 patients (mean age 21.5 ± 9.6 years) were included; 64{\%} had CHD. With a MVP device, mean Cum{\%}VP was 4.3 ± 14.6{\%} (range 0 to 83.7): Eleven patients were eligible for subgroup analysis. Compared with DDD(R), Cum{\%}VP significantly decreased with MVP (67.1 ± 29.4{\%} vs 9.2 ± 24.8{\%}, p = 0.002). One MVP-related adverse event occurred; a patient with intermittent atrioventricular block had symptoms with frequent nonconducted atrial depolarizations and was reprogrammed to DDD. In conclusion, MVP can be used safely and can significantly reduce unnecessary VP in pediatric patients and patients with CHD.",
author = "Kaltman, {Jonathan R.} and Ro, {Pamela S.} and Frank Zimmerman and Moak, {Jeffrey P.} and Michael Epstein and Zeltser, {Ilana J.} and Shah, {Maully J.} and Karen Buck and Vetter, {Victoria L.} and Tanel, {Ronn E.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.amjcard.2008.05.028",
language = "English (US)",
volume = "102",
pages = "875--878",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Managed Ventricular Pacing in Pediatric Patients and Patients With Congenital Heart Disease

AU - Kaltman, Jonathan R.

AU - Ro, Pamela S.

AU - Zimmerman, Frank

AU - Moak, Jeffrey P.

AU - Epstein, Michael

AU - Zeltser, Ilana J.

AU - Shah, Maully J.

AU - Buck, Karen

AU - Vetter, Victoria L.

AU - Tanel, Ronn E.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Ventricular dyssynchrony induced by ventricular pacing (VP) may predispose patients to congestive heart failure. The detrimental effects of VP are directly related to the cumulative percentage of VP (Cum%VP). Managed VP (MVP) is a novel pacing algorithm developed to minimize unnecessary VP by uncoupling atrial pacing from VP. This retrospective analysis assessed the feasibility of using MVP in pediatric patients and patients with congenital heart disease (CHD). A multicenter review evaluated all pediatric patients <22 years old and older patients with CHD that had an implanted device using a MVP algorithm. Primary outcome variables were Cum%VP and adverse events. A subgroup analysis evaluated patients that had a DDD(R) pacemaker before a MVP device and compared Cum%VP before and after initiation of MVP. From 6 centers 62 patients (mean age 21.5 ± 9.6 years) were included; 64% had CHD. With a MVP device, mean Cum%VP was 4.3 ± 14.6% (range 0 to 83.7): Eleven patients were eligible for subgroup analysis. Compared with DDD(R), Cum%VP significantly decreased with MVP (67.1 ± 29.4% vs 9.2 ± 24.8%, p = 0.002). One MVP-related adverse event occurred; a patient with intermittent atrioventricular block had symptoms with frequent nonconducted atrial depolarizations and was reprogrammed to DDD. In conclusion, MVP can be used safely and can significantly reduce unnecessary VP in pediatric patients and patients with CHD.

AB - Ventricular dyssynchrony induced by ventricular pacing (VP) may predispose patients to congestive heart failure. The detrimental effects of VP are directly related to the cumulative percentage of VP (Cum%VP). Managed VP (MVP) is a novel pacing algorithm developed to minimize unnecessary VP by uncoupling atrial pacing from VP. This retrospective analysis assessed the feasibility of using MVP in pediatric patients and patients with congenital heart disease (CHD). A multicenter review evaluated all pediatric patients <22 years old and older patients with CHD that had an implanted device using a MVP algorithm. Primary outcome variables were Cum%VP and adverse events. A subgroup analysis evaluated patients that had a DDD(R) pacemaker before a MVP device and compared Cum%VP before and after initiation of MVP. From 6 centers 62 patients (mean age 21.5 ± 9.6 years) were included; 64% had CHD. With a MVP device, mean Cum%VP was 4.3 ± 14.6% (range 0 to 83.7): Eleven patients were eligible for subgroup analysis. Compared with DDD(R), Cum%VP significantly decreased with MVP (67.1 ± 29.4% vs 9.2 ± 24.8%, p = 0.002). One MVP-related adverse event occurred; a patient with intermittent atrioventricular block had symptoms with frequent nonconducted atrial depolarizations and was reprogrammed to DDD. In conclusion, MVP can be used safely and can significantly reduce unnecessary VP in pediatric patients and patients with CHD.

UR - http://www.scopus.com/inward/record.url?scp=52349103162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52349103162&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2008.05.028

DO - 10.1016/j.amjcard.2008.05.028

M3 - Article

C2 - 18805114

AN - SCOPUS:52349103162

VL - 102

SP - 875

EP - 878

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -